Medication
Immunosuppressive Therapy (for Crohn's / UC)
- Back to work
- N/A
- Success rate
- 60-80% (for remission)
- Recurrence
- Variable
What it is
What is Immunosuppressive Therapy?
Immunosuppressive therapy is a cornerstone of medical management for moderate to severe Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis. These medications work by dampening the body's overactive immune response, which is responsible for the chronic inflammation of the gastrointestinal tract. The main classes of immunosuppressive drugs used in IBD are immunomodulators and biologic agents.
Immunomodulators
Immunomodulators, such as azathioprine, 6-mercaptopurine, and methotrexate, are oral medications that non-selectively suppress the immune system. They are typically used to maintain remission and as steroid-sparing agents. Their onset of action is slow, often taking 3-4 months to reach full therapeutic effect.
Biologic Agents
Biologic agents are monoclonal antibodies that target specific proteins involved in the inflammatory cascade. They are highly effective for both inducing and maintaining remission. Examples include anti-TNF agents (infliximab, adalimumab), anti-integrin agents (vedolizumab), and anti-interleukin agents (ustekinumab).
Am I a candidate?
Who are Good Candidates for Immunosuppressive Therapy?
Immunosuppressive therapy is indicated for patients with moderate to severe Crohn's Disease or Ulcerative Colitis who have not responded to or are intolerant of first-line therapies like 5-aminosalicylates and corticosteroids. It is also used for patients who are steroid-dependent or who have fistulizing or complex perianal disease. The choice of agent is highly individualized based on disease severity, location, patient preference, and risk factors.
Recovery
How is this Therapy Used?
Immunomodulators are taken orally on a daily basis. Biologic agents are administered either as intravenous infusions or subcutaneous injections at varying intervals (typically every 2 to 8 weeks). It is crucial for patients to adhere to their prescribed regimen to maintain disease control and prevent loss of response to the medication. Therapeutic drug monitoring is often used to optimize dosing and ensure adequate drug levels.
Risks & considerations
What are the Risks?
Immunosuppressive therapy carries significant risks due to its effect on the immune system. The primary risk is an increased susceptibility to infections, including opportunistic infections. Other risks include:
- Immunomodulators: Bone marrow suppression, pancreatitis, liver function abnormalities, and a small increased risk of lymphoma.
- Biologic Agents: Infusion reactions, allergic reactions, increased risk of infections (including tuberculosis), and a rare risk of lymphoma or other malignancies. Anti-TNF agents can also lead to the development of psoriasis or other autoimmune conditions.
Patients require close monitoring with regular blood tests and screening for infections like tuberculosis before starting biologic therapy.
Sources
- Steele SR, Hull TL, Hyman N, Maykel JA, Read TE, Whitlow CB, eds. The ASCRS Textbook of Colon and Rectal Surgery. 4th ed. Springer; 2022.
- American Society of Colon and Rectal Surgeons. (2020). Medical Management of Crohn's Disease. https://fascrs.org/patients/diseases-and-conditions/a-z/crohn-s-disease. Accessed October 15, 2025.